The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer.
AS Abdalla Al-Zawi - Medical Research Journal (2451-2591), 2021 - search.ebscohost.com
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer
ASA Al-Zawi - Medical Research Journal, 2021 - journals.viamedica.pl
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage …
CM Kelly, R Beamish, J McCaffrey, M Smith, J Crown… - 2013 - ascopubs.org
598 Background: Treatment planning for patients with node negative, ER-positive, HER-2
negative breast cancer often incorporates the use of prognostic and predictive tools like …
negative breast cancer often incorporates the use of prognostic and predictive tools like …
The association of clinical-pathologic factors and Oncotype Dx recurrence score (RS) in the outcome of early stage breast cancer.
M Chadha, R Stewart, J Wallach - 2015 - ascopubs.org
55 Background: Oncotype Dx recurrence score (RS) is routinely used to guide systemic
therapy based on the estimated risk for distant relapse. Patients with early stage disease are …
therapy based on the estimated risk for distant relapse. Patients with early stage disease are …
Abstract P2-07-11: Prediction of the Oncotype Dx recurrence score (RS) from clinicopathologic factors
IA Voutsadakis, S Thibodeau, M Reed - Cancer Research, 2019 - AACR
Abstract Background: The Oncotype Dx assay is currently used as an aid to therapeutic
decisions for the adjuvant treatment of women with ER-positive, Her2-negative, lymph node …
decisions for the adjuvant treatment of women with ER-positive, Her2-negative, lymph node …
The effect of oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor–positive early stage breast cancer and correlation with …
JE Joh, NN Esposito, JV Kiluk, C Laronga… - The …, 2011 - academic.oup.com
Abstract Purpose. The Oncotype DX assay predicts likelihood of distant recurrence and
improves patient selection for adjuvant chemotherapy in estrogen receptor–positive (ER …
improves patient selection for adjuvant chemotherapy in estrogen receptor–positive (ER …
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
J Asad, AF Jacobson, A Estabrook, SR Smith… - The American journal of …, 2008 - Elsevier
BACKGROUND: Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence
in women with estrogen-receptor–positive, lymph node–negative breast cancer. The …
in women with estrogen-receptor–positive, lymph node–negative breast cancer. The …
The correlation between the Oncotype DX recurrence score and Ki-67 proliferation index in ER+ ve, HER2− ve, node negative breast cancer
ASA Al-Zawi, M Barron, W Chicken, Z Aladili… - European Journal of …, 2022 - ejso.com
Background: The Oncotype DX recurrence score (RS) is a 21 gene panel assay developed
to predict the risk of recurrence in patients with ER+ ve, HER2− ve, node negative breast …
to predict the risk of recurrence in patients with ER+ ve, HER2− ve, node negative breast …
Impact of oncotype DX recurrence score in the management of breast cancer cases
MT Nguyen, A Stessin, H Nagar, TM D'Alfonso… - Clinical breast …, 2014 - Elsevier
Background Oncologists have used clinicopathologic features to guide treatment decisions
for their breast cancer patients; however, more recently, results of multigene assays are also …
for their breast cancer patients; however, more recently, results of multigene assays are also …
Evaluation of relation between Oncotype DX recurrence score and adjuvant chemotherapy administration.
DR Kazzaz, C Chen, J Shankleton… - Journal of Clinical …, 2011 - ascopubs.org
e11105 Background: The Onco type DX Recurrence Score (RS) is a clinically validated
molecular test that can be used to predict the risk of distant recurrence and the likelihood of …
molecular test that can be used to predict the risk of distant recurrence and the likelihood of …